On November 17, Summit Therapeutics PLC fell 4.1% in Regular Trading, trading at $11.33 per share, with turnover of $8.07 million.
The move follows the company’s disclosure that the FDA issued a complete response letter for ivonescimab in previously treated advanced lung cancer, meaning the current application was not approved and pressuring sentiment for the company’s lead asset.
According to the company update, the FDA concluded that progression-free survival benefit alone was insufficient to support a favorable benefit-risk profile without evidence of overall survival improvement. Summit Therapeutics PLC also did not provide a timeline for resubmission or specify what additional evidence it may submit, leaving the regulatory path and commercialization timing less certain. Earlier reports indicated the news had already triggered sharp premarket and intraday selling, and the continued weakness suggests the market is still repricing regulatory and development risk around ivonescimab.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments